Randomized, placebo-controlled, double-blind, phase 2 study of AG-013736 in combination with docetaxel versus docetaxel alone in patients with metastatic breast cancer preceded by a phase 1 evaluation of the combination.

Trial Profile

Randomized, placebo-controlled, double-blind, phase 2 study of AG-013736 in combination with docetaxel versus docetaxel alone in patients with metastatic breast cancer preceded by a phase 1 evaluation of the combination.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Jun 2012

At a glance

  • Drugs Axitinib; Docetaxel
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 May 2011 Results published in the Journal of Clinical Oncology.
    • 20 Dec 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Sep 2008 Planned end date changed from Sep 2008 to Oct 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top